drugset / Trial / NCT06821542
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
Timeline
- Start
- 2025-06-04
- Primary completion
- 2028-05-31
- Completion
- 2032-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCA034176 | Unknown | — | Intravenous |
| Background | Cyclosporine | Peptide | — | — |
| Background | Everolimus | Small molecule | — | — |
| Background | Ibrutinib | Small molecule | — | — |
| Background | Imatinib | Small molecule | — | — |
| Background | Mycophenolate mofetil (MMF) | Unknown | — | — |
| Background | Pentostatin | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |
| Background | Sirolimus | Small molecule | — | — |
| Background | Tacrolimus | Small molecule | — | — |